Document is current

Article History

Received: 30 May 2023

Accepted: 28 July 2023

First Online: 17 August 2023

Declarations

:

: This article does not contain any studies with human participants or animals performed by any of the authors. For this type of study informed consent is not required.

: For this type of study consent for publication is not required.

: Sanjeeva P. Kalva reports grants from NIH, BD, Black Swan, and Trisalus for Institution; reports royalties from Elsevier, Springer, and Thieme for himself; reports consulting fees from Penumbra, Okami Medical, Boston Scientific, Medtronic, Instylla, and BD for himself; reports stock from Biogen Inc, Clover Health Investments Corp, Inovio Pharmaceuticals, Moderna Inc, Pfizer Inc, Novavax Inc, Orphazyme, Cassava Sciences Inc, Vivos Therapeutics Inc, Ardelyx Inc, Althea Health, Sarepta Therapeutics, Clover Health Investments Corp, CureVac BV, Immunoprecise Antibodies Ltd, Infinity Pharmaceuticals Inc, Zymergen Inc, BioNTech SE, Trillium Therapeutics Inc, Theravance Biopharma Inc, Doximity Inc, Eargo Inc, Allogent Therapeutics Inc, NRx Pharmaceuticals Inc, Atea pharmaceuticals Inc, for himself and spouse.Patrick D. Sutphin reports the following disclosures:Research Funding: TriSalus Life Sciences, Inc., Instylla, Inc. (pending).Stocks: Amwell, Axcella, Crispr Therapeutics, CVS Health Corp, Editas Medicine, Gilead Sciences, Inc., Intellia Therapeutics, Jazz Pharmaceuticals, Teladoc Health Inc, Rubius Therapeutics.Stocks Recently (owned): Viewray Inc.The other authors (SH, OZ) report no conflicts of interest.